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Abstract
Sepsis-induced cardiomyopathy is a reversible myocardial dysfunction that typically resolves in 7–10 days. It is
characterized by left ventricular dilatation and depressed ejection fraction. However, many uncertainties exist
regarding the mechanisms, characteristics, and treatments of this condition. Therefore, this review attempts to
summarize our current knowledge of sepsis-induced cardiomyopathy.
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Introduction
Sepsis is a dysregulated systemic inflammation caused
by infections involving various organs. Sepsis-induced
cardiomyopathy is a complication of severe sepsis and
septic shock first described by Parker et al. in 1984 as a
reversible myocardial depression that occurs in patients
with septic shock [1]. In sepsis-induced cardiomyopathy,
the myocardium is functionally and structurally injured by
inflammatory cytokines and mitochondrial dysfunction.
However, our understanding regarding this condition
remains incomplete. Recently, the development of tools,
including echocardiography, has made it possible to
visualize the hemodynamics of sepsis-induced cardio-
myopathy. Sepsis-induced cardiomyopathy has three
characteristics: left ventricular dilatation, depressed ejection
fraction, and recovery in 7–10 days. Also, advances in mo-
lecular biology have made understanding the mechanisms
of sepsis-induced cardiomyopathy possible (Fig. 1).
Chemical mediators, including endotoxins, cytokines,
and nitric oxide, appear to be the main mediators of
sepsis-induced cardiomyopathy. The treatment strategy of
sepsis-induced cardiomyopathy is the same with the
adequate treatment of sepsis without cardiomyopathy. Al-
though dobutamine is recommended in current guidance,
recent trials have demonstrated that in patients with
sepsis, it does not improve the prognosis and may have ad-
verse effects. Here, we discuss the mechanisms, characteris-
tics, and treatments of sepsis-induced cardiomyopathy.
Review
Characteristics of sepsis-induced cardiomyopathy
In 1984, Parker et al. reported decreased ejection frac-
tion and increased end-diastolic volume in septic shock
survivors. These changes in left ventricular function
were of rapid onset and reversed over 7–10 days in sur-
vivors; however, they were less profound in those who
died [1, 2]. Moreover, Vieillard et al. demonstrated the
mortality rate among patients in a hyperkinetic state to
be significantly higher than that among patients in either
a hypokinetic or normal-output state (100 vs 43 and
24 %) [3]. Conversely, a recent meta-analysis suggested
that ventricular dysfunction or dilatation in patients with
sepsis was not associated with lower mortality [4]. It
suggested that mortality does not depend on whether
the patients have sepsis-induced cardiomyopathy or not;
however, it depends on whether the patient’s heart is
hyperkinetic or not. Because patients with sepsis-induced
cardiomyopathy tend to be either hypokinetic or normoki-
netic but not hyperkinetic, in patients with sepsis-induced
cardiomyopathy, the outcomes may be better than in
patients without sepsis-induced cardiomyopathy. Larger
studies are needed to clarify whether sepsis-induced
cardiomyopathy is associated with improved outcomes.
Sepsis also triggers takotsubo cardiomyopathy, also
known as stress cardiomyopathy, apical ballooning syn-
drome, or broken-heart syndrome, which is different from
sepsis-induced cardiomyopathy. Takotsubo cardiomyopathy
typically occurs when the contractile function of the mid-
to-apical segments of the left ventricle is depressed and
there is hyperkinesis of basal walls, producing a balloon-
like appearance of the distal ventricle. Several studies have
reported that this syndrome is induced by increased
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catecholamine levels. In takotsubo cardiomyopathy, the
left ventricular function usually returns to normal within a
few weeks. At a cellular level, changes were shown to be re-
versible with normalization of the left ventricular ejection
fraction, including the cytoskeletal protein derangements,
increase in extracellular matrix proteins, and accumulation
of intracellular glycogen [5]. Although sepsis and septic
shock can trigger takotsubo cardiomyopathy, the etiology
and myocardial alterations appear to be different from
those of sepsis-induced cardiomyopathy. In sepsis-induced
cardiomyopathy, there is global ventricular dysfunction
and dilated left ventricle without regional dysfunction.
In takotsubo cardiomyopathy, there is typically regional
dysfunction, especially characterized by apical ballooning
mimicking acute coronary syndrome. Therefore, the ac-
curate diagnosis of takotsubo cardiomyopathy requires
coronary angiography to rule out acute coronary syndrome.
In addition, many reports on takotsubo cardiomyopathy
have mentioned various underlying diseases; this suggests
that the pathophysiology of takotsubo cardiomyopathy is
not specific to one particular disease. For these reasons,
sepsis-induced cardiomyopathy and takotsubo cardio-
myopathy are two different entities.
Despite the lack of diagnostic criteria for sepsis-induced
cardiomyopathy to date, it is known to have three charac-
teristics. The first is left ventricular dilatation with normal
or low filling pressure. This probably occurs due to an in-
crease in the left ventricular compliance, which was first
described in patients with septic shock in 1984 [1]. Later,
another study of the left ventricle response to volume
loading showed that there was an abnormal increase in left
ventricular end-diastolic volume in sepsis survivors, im-
plying increased ventricular compliance [6]. The second
characteristic is depressed ejection fraction. Parker et al.
reported that end-diastolic and systolic ventricular vol-
umes were increased but with normal or elevated stroke
volume and cardiac index in septic shock survivors. In this
study, although the number of patients is less, these
results suggest that decreased ejection fraction may be
caused by ventricular dilatation and not by decreased
stroke volume. Because ejection fraction is defined as
the stroke volume divided by the end-diastolic ventricular
volume, the denominator increases as the ejection fraction
decreases [7]. Vincent et al. demonstrated that the left
and right ventricular ejection fractions are depressed
in patients with septic shock [8]. Other studies support
this result and have shown the development of right ven-
tricular dilatation [6, 9, 10]. The third characteristic of
sepsis-induced cardiomyopathy is that it should normalize
within 7–10 days [1, 11, 12]. In sepsis-induced cardiomy-
opathy diagnosis, the first and second characteristics are
particularly important and easy to detect using echocardi-
ography. Thus, echocardiography in sepsis management is
the most important thing for diagnosing sepsis-induced
cardiomyopathy.
B-type natriuretic peptide (BNP), a diuretic hormone,
is released from ventricular myocardium in response to
cardiac wall stretch. Recent observational study demon-
strated that sepsis-induced cardiomyopathy is associated
with BNP rise, although not independently, whereas left
ventricular filling pressures do not correlate with the
BNP levels [13]. In this study, the author concluded that
the severity of critical illness, rather than sepsis-induced
cardiomyopathy, is probably the main determinant of
BNP rise in critical patients with sepsis. For this reason,
BNP should not be used as a predictive marker of
sepsis-induced cardiomyopathy.
Troponin is a very sensitive and specific protein of
myocardial damage and often used for the diagnosis of
acute coronary syndrome (ACS). Troponin elevation is
common in septic shock patients, and it was estimated
that 43–85 % of patients with sepsis showed cardiac
troponin I elevation [14–16]. Bessiere et al. performed a
meta-analysis and reported that troponin elevation is as-
sociated with a higher risk of death among patients with
Fig. 1 Mechanisms of sepsis-induced cardiomyopathy. Endotoxins
cause depressed cardiac contractility, which is mediated by enhanced
nitric oxide (NO) production. Tumor necrosis factor and interleukin-1β
also contribute to NO overproduction. NO is believed to act in
the heart by decreasing myofibril response to calcium, inducing
mitochondrial dysfunction, and downregulating β-adrenergic
receptors. These reactions lead to sepsis-induced cardiomyopathy.
Methylene blue, an inhibitor of the NO pathway, counteracts the
myocardial depression. Histones occur inside the nucleus and can
be released into circulation because of extensive inflammation and
cellular death during sepsis. Since cardiac dysfunction can be ameliorated
by anti-histone antibodies in a septic mouse model, histones may be
implicated in the pathophysiology of sepsis-induced cardiomyopathy
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sepsis [17]. However, the use of troponin to diagnose
sepsis-induced cardiomyopathy is limited because there
are many causes such as ACS and low renal function
that affect troponin levels.
The mechanisms of sepsis-induced cardiomyopathy
Two possible causative mechanisms have been proposed
to explain sepsis-induced cardiomyopathy. First, myocardial
ischemia resulting from inadequate coronary blood flow
has been proposed on the basis of a study in animals [18].
Second, there are strong arguments that chemical media-
tors, such as endotoxins, cytokines, and nitric oxide, are
causative. To determine whether myocardial depression
in humans with septic shock was associated with reduced
coronary flow, a study was conducted that used coronary
sinus thermodilution catheters to measure coronary flow
and myocardial metabolism in seven patients [19]. Myo-
cardial depression was observed in four of the seven pa-
tients who had coronary flow similar to or higher than
that of controls and similar to that of other three patients.
Therefore, reduced coronary flow may not contribute to
the pathogenesis of sepsis-induced cardiomyopathy.
Concerning the role of chemical mediators, there are
stronger arguments to support their role in sepsis-induced
cardiomyopathy. Anthony et al. demonstrated that endo-
toxin administration to controls caused the left ventricular
function to become depressed [20], with left ventricular
end- and end-systolic volume indexes increasing by 18
and 24 %, respectively. Flesch et al. also demonstrated
that exposure of the myocardium to endotoxins caused
depressed cardiac contractility, which was mediated by
enhanced inducible nitric oxide synthase activity and
nitric oxide release [21]. In 1985, Parriio et al. demon-
strated in vitro that myocardial cell shortening was re-
duced by exposure to the serum of patients with sepsis
[22]. The same team later showed that this response
was caused by tumor necrosis factor alpha (TNF-α)
[23], which was confirmed when Vincent et al. demon-
strated that anti-TNF antibody administration improved
ventricular function without changing the cardiac filling
pressure [24]. In a more recent study, interleukin-1β has
also been implicated [25], further supporting cytokine’s
role in sepsis-induced cardiomyopathy.
Kumar et al. have suggested that cytokine’s effect on
cardiac myocytes results from an increase in both intracel-
lular cyclic guanosine monophosphate and nitric oxide
[26]. Because the half-lives of TNF and interleukin-1β are
less than 6 h, nitric oxide appears to have an important
contributory role in the pathogenesis of sepsis-induced
cardiomyopathy. Nitric oxide is thought to act in the heart
by decreasing myofibril response to calcium [27], inducing
mitochondrial dysfunction [28], and downregulating β-
adrenergic receptors [28, 29]. Some studies reported that
the severity of cardiac dysfunction and mortality can be
related to nitric oxide overproduction and mitochondrial
dysfunction [30–32]. Larche et al. demonstrated that
mitochondrial dysfunction in sepsis is causative rather
than epiphenomenal and relevant in terms of myocardial
dysfunction in sepsis [33]. In 2001, Kirov et al. evaluated
the effects of continuous infusion of methylene blue, an in-
hibitor of the nitric oxide pathway, on the hemodynamics
and organ function of patients with septic shock. They
reported that continuous infusion of methylene blue
counteracted the myocardial depression, maintained oxy-
gen transport, and reduced the need for concurrent adren-
ergic support [34]. Later, in a systematic review, Kwok
et al. reported that methylene blue administration during
sepsis increased the mean arterial pressure and systemic
vascular resistance while decreasing the vasopressor
requirement [35].
A recent study demonstrated that high-circulating his-
tone levels were significantly associated with new-onset
left ventricular dysfunction and arrhythmias in patients
with sepsis with no previous cardiac dysfunction [36].
However, because histones occur inside the nucleus and
can be released into circulation because of extensive in-
flammation and cellular death during sepsis, it is unclear
whether the circulating histones are the cause or the re-
sult of sepsis-induced cardiomyopathy. Further research
is warranted to decide the role of circulating histones in
the pathogenesis of sepsis-induced cardiomyopathy.
Although the reason why sepsis-induced cardiomyop-
athy resolves within 7–10 days is poorly understood, the
mechanisms proposed in this section appear to be crit-
ical. In particular, chemical mediators, such as endo-
toxins and cytokines, are currently regarded as the most
likely cause of sepsis-induced cardiomyopathy. However,
the mechanism of myocardial recovery in sepsis-induced
cardiomyopathy is poorly understood, and further re-
search is clearly needed.
Treatments for sepsis-induced cardiomyopathy
In 2001, Rivers et al. reported that early goal-directed
therapy was effective for severe sepsis management.
Although this strategy has become a standard therapy
worldwide, the original study was only a small single-
center study [37]. The ProCESS [38] and ARISE [39]
trials (in 2014) and the ProMiSe trial [40] (in 2015) have
since demonstrated that early goal-directed therapy did
not improve outcomes compared with usual care. There is
a widespread agreement that standard treatment for sepsis
should focus on infection control and optimization of
hemodynamic parameters by fluid resuscitation and vaso-
pressor therapy. This strategy is also recognized as the
standard therapy for sepsis-induced cardiomyopathy. Nor-
adrenaline is recommended as a first-line vasopressor;
however, some studies reported that vasopressin also may
be effective for septic shock. Russell et al. suggested that
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low-dose vasopressin may reduce the mortality of patients
with less severe septic shock, although there was no sig-
nificant difference between vasopressin and noradrenaline
in the 28- and 90-day mortality of all patients with septic
shock [41]. From this finding, current guidance describes
that low-dose vasopressin can be added to noradrenaline
with the intent of either raising mean arterial pressure
or decreasing noradrenaline dosage; however, low-dose
vasopressin is not recommended as a single vasopressor
[42]. Mehta et al. reported that troponin, CK, and ECG
are not different in patients with septic shock who are
treated with noradrenaline and vasopressin [43]. This find-
ing suggests that vasopressin also may be effective for the
management of sepsis-induced cardiomyopathy. However,
further study is warranted to confirm the effectiveness of
vasopressin.
Current guidance recommends using dobutamine [42]
to increase the cardiac index [44]. However, Gattinoni et
al. reported that hemodynamic therapy with dobutamine
and dopamine to achieve supranormal values for the car-
diac index failed to reduce morbidity or mortality among
critically ill patients [45]. Michelle et al. also demonstrated
that the use of dobutamine to boost the cardiac index did
not improve the outcome of critically ill patients [46]. Fur-
thermore, Wilkman et al. reported that the use of dobuta-
mine was associated with increased 90-day mortality from
septic shock [47], while Hernandez et al. demonstrated
that dobutamine did not improve sublingual microcircula-
tory, metabolic, hepatosplanchnic, or peripheral perfusion
parameters in patients with septic shock [48].
Lyte et al. suggested that the ability of inotropic cat-
echolamines to stimulate bacterial proliferation and
biofilm formation might be an etiological factor in the
development of intravascular catheter colonization and
catheter-related infection [49]. This effect of inotropic
catecholamines does not seem to be limited to only
coagulase-negative Staphylococcus but also other gram-
negative bacteria. The growth of these bacteria and
production of virulence are associated with inotropic cate-
cholamines [49]. Thus, inotropic catecholamines, such as
dobutamine, may have adverse effects in patients with sep-
tic shock, and the decrease in β-adrenergic response in
patients with sepsis-induced cardiomyopathy may be a
protective mechanism to these effects. Morelli et al.
suggest that β-blockade could be associated with reduc-
tions in the heart rate without adverse effects and that
this could help to improve survival [50]. Although the
mortality in the control group of their study was high,
the study provided interesting preliminary data suggest-
ing that β-blockade may be effective in septic shock
treatment. For these reasons, despite the beneficial ef-
fects of dobutamine, it appears that excessive increases
in sympathetic tone during sepsis can create adverse
effects.
Levosimendan can increase contractile myofilament
sensitivity to calcium and is a positive inotropic drug.
Levosimendan sensitizes troponin C to calcium in a cal-
cium concentration-dependent manner; this increases
the effects of calcium on myofilaments during systole.
This sensitization is diminished by decreasing calcium
concentration level during diastole, and thus, diastolic
relaxation remains largely unaffected. In contrast to
other inotropic agents, levosimendan does not cause ar-
rhythmias or increase the oxygen consumption. It also
opens the ATP-sensitive potassium channels causing
smooth muscle membrane hyperpolarization which leads
to vasodilation. A meta-analysis evaluated the use of
levosimendan in septic shock [51] and reported that it
was associated with reduced mortality when compared
with standard inotropic therapy. Although levosimendan is
also an inotropic agent, it does not stimulate β-adrenergic
receptor. This may be the reason why levosimendan can be
effective to the patients with septic shock, despite dobuta-
mine seems to create adverse effect in the patients with
septic shock. To confirm this finding, a larger multicenter
randomized trial is needed to assess the effectiveness of
levosimendan in sepsis-induced cardiomyopathy.
Intra-aortic balloon pumping (IABP) is expected to
increase the cardiac output and reduce the dosage of a
vasopressor. Solomon et al. demonstrated that in a canine
model of severe septic shock with a low cardiac index,
IABP prolongs survival time and lowers vasopressor re-
quirements [52]. Nakamura et al. reported two cases of
severe sepsis-induced cardiomyopathy with refractory
shock [53]. To our knowledge, this is the only report in
which polymyxin B-immobilized fiber column-direct
hemoperfusion (PMX-DHP) and IABP were used for
the management of sepsis-induced cardiomyopathy. Al-
though the authors suggested their use in sepsis-induced
cardiomyopathy, their effectiveness and safety are not yet
developed and their use in the management of septic
shock are currently at an experimental stage. For example,
a recent multicenter randomized controlled trial demon-
strated a non-significant increase in mortality and no im-
provement in organ failure with PMX-DHP compared to
the conventional treatment in patients with septic shock
due to peritonitis [54]. There are some case reports of the
successful use of veno-arterial extracorporeal membrane
oxygenation (ECMO) as the last rescue therapy to unre-
sponsive severe cardiogenic shock in patients with sepsis-
induced cardiomyopathy. We searched PubMed (January
1990 to September 2015) for English language articles for
sepsis-induced cardiomyopathy treated with veno-arterial
ECMO. The keywords “sepsis” OR “septic shock” AND
“extracorporeal membrane oxygenation” were used and
we carefully reviewed the articles found. The adult patients
with sepsis-induced cardiomyopathy who received veno-
arterial ECMO support are listed in Table 1 [55–63]. This
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strategy may provide time for antibiotics to work effectively.
If both septic and cardiogenic factors contribute to the
pathophysiology of shock, veno-arterial ECMO may im-
prove the mortality of the most severe group. However, the
experience of the use of ECMO in patients with septic
shock is very limited. Moreover, the management of
patients who need ECMO is very complex; thus, a
well-experienced team should use it in a specialized
center [64]. For these reasons, to date, mechanical
support with IABP or ECMO seems not to be a standard
therapy, although it may be the last option for unre-
sponsive severe cardiogenic shock due to sepsis-induced
cardiomyopathy.
Summary of our current knowledge
Sepsis-induced cardiomyopathy is characterized by left
ventricular dilatation and depressed ejection fraction
that typically normalize within 7–10 days. Our current
understanding is that sepsis-induced cardiomyopathy is
induced by endotoxins and cytokines and that the initial
management should be the same as for septic shock
without cardiomyopathy. However, the lack of quality
evidence that dobutamine improves survival and the
concerning reports that it may adversely affect outcomes
in patients with sepsis imply that the routine use of do-
butamine should no longer be recommended. In the
near future, levosimendan or mechanical support with
ECMO may be developed as a therapeutic option, but
further study is needed to confirm whether it is truly ef-
fective in sepsis-induced cardiomyopathy.
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Table 1 Reported cases of the patients with sepsis-induced cardiomyopathy who received veno-arterial extracorporeal membrane
oxygenation support
Article Age Sex Infection Survival
Pořízka M et al. 2015 [55] 31 M Necrotizing fasciitis +
Fujisaki N et al.2014 [56] 27 F CA pneumonia +
Endo A et al. 2014 [57] 41 M Purpura fulminans −
Bréchot N et al. 2013 [58] 33 M CA pneumonia +
Bréchot N et al. 2013 [58] 62 M CA pneumonia +
Bréchot N et al. 2013 [58] 31 F Acute cholecystitis +
Bréchot N et al. 2013 [58] 33 F Aspiration pneumonia +
Bréchot N et al. 2013 [58] 48 F CA pneumonia −
Bréchot N et al. 2013 [58] 66 M Peritonitis after liver transplant −
Bréchot N et al. 2013 [58] 59 M CA pneumonia +
Bréchot N et al. 2013 [58] 52 M CA pneumonia −
Bréchot N et al. 2013 [58] 28 F CA pneumonia +
Bréchot N et al. 2013 [58] 35 M Aspiration pneumonia +
Bréchot N et al. 2013 [58] 28 F Aspiration pneumonia +
Bréchot N et al. 2013 [58] 52 F Nosocomial pneumonia +
Bréchot N et al. 2013 [58] 57 F Pharyngitis +
Bréchot N et al. 2013 [58] 48 M CA pneumonia −
Hagiwara et al. 2013 [59] 69 M Klebsiella bacteremia +
Firstenberg MS et al. 2010 [60] 18 M Necrotizing fasciitis +
Firstenberg MS et al. 2010 [60] 39 F Necrotizing fasciitis +
MacLaren G et al. 2010 [61] 29 F H1N1 influenza +
Vohra HA et al. 2009 [62] 18 M Mediastinitis after Ravitch procedure +
McLauren G et al. 2004 [63] 22 M Vertebral osteomyelitis +
CA community acquired, M male, F female
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